2021 Online, In the cloud

I-43 Emma Eckernäs
Population pharmacokinetic/pharmacodynamic modelling of the psychedelic experience induced by N,N-dimethyltryptamine
I-44 Berfin Gülave
Opioids distribution in human CNS might be altered due to pain-related increase of BBB permeability.
I-45 Hee Yoon Jung
Equivalent dose prediction of donepezil patch using population pharmacokinetic oral and patch combination model
I-46 Tatiana Karelina
Quantitative systems pharmacology model of axonal degeneration markers in Alzheimer’s disease
I-47 Orestis Papasouliotis
Phase III dose selection for evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor: exposure-response analyses from a phase II study in patients with multiple sclerosis
I-48 Satoshi Shoji
Population Pharmacokinetic Analysis of Tanezumab, a Novel Monoclonal Antibody to Nerve Growth Factor, Following Intravenous or Subcutaneous Administration to Patients with Osteoarthritis or Chronic Low Back Pain in Phase 2b and Phase 3 Studies
I-49 Satoshi Shoji
Prediction of Free Target Suppression Following Subcutaneous Administration of Tanezumab Based on Target-mediated Drug Disposition Approximation Model
I-50 Hanna Silber Baumann
Population pharmacokinetic analysis of Satralizumab in NMOSD patients and healthy volunteers.